BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $15.60.

A number of equities analysts have recently weighed in on the company. Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, JMP Securities upped their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. Franklin Resources Inc. increased its position in shares of BioCryst Pharmaceuticals by 177.8% during the third quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 168,790 shares during the period. Sanctuary Advisors LLC increased its holdings in BioCryst Pharmaceuticals by 78.3% during the 3rd quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 20,818 shares during the period. SkyView Investment Advisors LLC raised its position in BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 3,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after buying an additional 127,708 shares during the period. Finally, Wellington Management Group LLP acquired a new position in shares of BioCryst Pharmaceuticals during the third quarter worth about $819,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.19 on Wednesday. The company’s 50-day moving average is $7.58 and its two-hundred day moving average is $7.32. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.88. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -11.79 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The company’s revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.19) earnings per share. As a group, equities analysts anticipate that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.